COVID-19 has ravaged the medical, social, and financial landscape across the world, and the USA–Mexico border is no exception. Although some risk factors for COVID-19 severity and mortality have already been identified in various ethnic cohorts, there remains a paucity of data among Hispanics, particularly those living on borders. Ethnic disparities in COVID-19 outcomes in Hispanic and black populations have been reported. We sought to identify the clinical presentation, treatment, laboratory, and imaging characteristics of 82 Hispanic patients in a county hospital and describe the factors associated with rates of hospitalization, intensive care unit (ICU) admission, and mortality. The most common comorbidities were hypertension (48.8%) and diabetes mellitus (DM) (39%), both found to be associated with hospitalization and mortality, while only DM was associated with increased rate of ICU admission. Multivariable analysis showed that individuals with fever, low oxygen saturation (SpO2), nasal congestion, shortness of breath, and DM had an increased risk of hospitalization. Individuals with fever, decreased levels of SpO2, and advanced age were found to be associated with an increased risk of death. The most common cause of death was respiratory failure (28.9%), followed by shock (17.8%) and acute kidney injury (15.6%). Our findings are critical to developing strategies and identifying at-risk individuals in a Hispanic population living on borders. Research aiming to identify key evidence‐based prognostic factors in our patient population will help inform our healthcare providers so that best interventions can be implemented to improve the outcomes of patients with COVID-19.
- intensive care units
- diabetes mellitus
This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.https://bmj.com/coronavirus/usage
Statistics from Altmetric.com
Significance of this study
What is already known about this subject?
Ethnic disparities in COVID-19 outcomes in Hispanic and black populations have been reported, with higher fatality rates shown in Hispanic and black populations compared with white non-Hispanics.
There remains a paucity of data with regard to Hispanics, particularly those living on borders.
What are the new findings?
We evaluated variables that are known to influence the clinical course and severity of COVID-19 hospitalization among Hispanic patients on the USA–Mexico border.
Using multivariable analysis, we found that individuals with fever, low oxygen saturation (SpO2), nasal congestion, shortness of breath, and diabetes mellitus had an increased risk of hospitalization.
Individuals with fever, decreased levels of SpO2, and advanced age were found to be associated with an increased risk of death.
The most common cause of death was respiratory failure (28.9%), followed by shock (17.8%) and acute kidney injury (15.6%).
How might these results change the focus of research or clinical practice?
Our findings are critical to developing strategies and identifying at-risk individuals in a Hispanic population living on borders.
Research aiming to identify key evidence‐based prognostic factors in our patient population will help inform our healthcare providers so that best interventions can be implemented to improve the outcomes of patients with COVID-19.
In late December 2019, reports from China brought to the attention of the world a newly discovered coronavirus named SARS-CoV-2. Due to its highly contagious human-to-human transmission, SARS-CoV-2 infection rapidly spread worldwide, and the WHO declared COVID-19 a pandemic on March 13, 2020.1 Although majority of patients with COVID-19 recovered without the need for a specific medical intervention, approximately 20% of patients required inpatient hospital care. About 5% of patients necessitated admission to the intensive care unit (ICU) and often required mechanical ventilator support.2 3 With an estimated overall mortality of between 1% and 5% to date,3–6 there is still a significant number of unknown epidemiological, clinical, and prognostic factors about this disease.
Most of the data reported related to COVID-19 management and outcomes in the USA have come from the country’s northeastern region. Recent studies showed racial/ethnic differences in clinical presentation and outcomes in patients with COVID-19, with Hispanics affected by higher fatality rates.7 8 Most of these studies did not include Hispanics of Mexican origin, who are considered even more vulnerable to the infection and its adverse outcomes due to lack of resources and accessibility and due to cultural beliefs. The USA–Mexico border has a unique ethnic distribution compared with other regions in the USA, with approximately 80% of our patient population comprising Hispanics. Since it is known that genetic patterns are associated with a higher risk of certain infectious diseases, it will be useful to understand the clinical features and associated comorbidities of COVID-19 in our Hispanic population. Therefore, it is relevant to improve our knowledge on the behavior of this disease in the southwest region of the country, particularly on the USA–Mexico border. Identifying specific characteristics associated with COVID-19 severity and mortality will help healthcare professionals screen at-risk patients with COVID-19 early and provide better management.
We sought to describe the clinical presentation, treatment profile, and COVID-19 outcomes of Hispanic patients admitted to a county hospital on the USA–Mexico border and to evaluate the factors associated with COVID-19 severity as determined by ICU admission, hospitalization, and mortality.
Materials and methods
Subjects and data
The study used inpatient and outpatient electronic medical record data from the University Medical Center of El Paso, Texas, and its various satellite clinics from March 1 to May 28, 2020. Outpatients included patients seen in clinics who tested positive for SARS-CoV-2, in addition to patients who were seen in the emergency department (ED) who tested positive but were not admitted to the hospital. We did not include any patients who tested positive but were not seen in a clinical setting (ie, clinic, ED). General demographics, comorbidities, symptoms, laboratory findings, imaging findings, and treatment received including ICU admission information from 89 inpatients and 22 outpatients with confirmed COVID-19 were reviewed. Only diagnoses of COVID-19 confirmed by a positive SARS-CoV-2 test with presence of symptomatology were included in this study. Non-Hispanic patients were excluded.
The primary outcomes considered in this study were severity of COVID-19 as measured by hospitalization, ICU admission, and in-hospital mortality. The secondary outcomes included complications such as septic shock, acute respiratory distress syndrome, acute kidney injury, disseminated intravascular coagulation, deep venous thrombosis, rhabdomyolysis, hepatitis, cerebrovascular accident, secondary bacterial or fungal infection, pancreatitis, and acute coronary syndrome.
A large number of demographic and clinical variables were also collected (online supplemental tables 1 and 2).
Quantitative variables were described using mean, SD, median, and IQR depending on the distribution of variables. Categorical variables were described using frequency and proportions. All covariates, including demographic, clinical, laboratory, imaging, and treatment profiles, were compared according to hospitalization, ICU admission, and mortality status using either Student’s t-test or χ2 test as per the type of cofactors. For non-normal variables, the Wilcoxon rank-sum test instead of a t-test was used. Generalized linear models with a family Poisson and log link were used to determine factors associated with hospitalization, ICU admission, and mortality separately. Only significant variables with limited missing data from the unadjusted analysis were included in the final multivariable model with a backward stepwise elimination approach to determine variables associated with each primary outcome. The results were summarized with relative risk along with 95% CI and p value. Skewed laboratory values were transformed and included in the model. Spearman rank correlations were used to assess the association between number of days in ICU and quantitative variables. P values less than 5% were considered statistically significant. All analyses were carried out using STATA V.15.1.
General demographics and outcomes
Of the 111 subjects, 82 were included in the final analysis. Thirty-five were women (43%), with an average age of 55 years old and an average body mass index (BMI) of 30 (SD: 5.7) kg/m2 (table 1). A total of 15 in-hospital deaths (18.3%; 95% CI) were observed, with 74.4% hospitalizations (n=61) and 24.4% ICU admissions (n=20). The most common cause of death was respiratory failure (28.9%), followed by shock (17.8%) and acute kidney injury (15.6%). The average number of days in the ICU was 1.94 (SD: 4.7) (table 2). None of the considered demographic characteristics was associated with any outcomes except age.
Majority of patients had at least two chronic conditions (47.6%), followed by one chronic condition (16, 19.5%). Among individual comorbidities, the most common were hypertension (HTN) (48.8%) and diabetes mellitus (DM) (39%). Both DM and HTN were found to be associated with hospitalization and mortality, while only DM was associated with increased rate of ICU admission. Patients with two or more conditions were strongly associated with COVID-19 severity (hospitalization and mortality), but not with in-hospital mortality (table 3). Other medical conditions included coronary artery disease, cerebrovascular disease, cancer, chronic kidney disease, asthma, cirrhosis, hepatitis, hypothyroidism, HIV, and inflammatory bowel disease.
Factors associated with hospitalization
In unadjusted analyses, numerous variables, including age, signs and symptoms, presence of any signs, laboratory and radiological abnormalities, as well as chronic conditions such as DM and HTN, were found to be associated with hospitalization (shown in online supplemental table 1). However, in multivariable analysis, individuals with increased levels of body temperature, nasal congestion, low oxygen saturation (SpO2), shortness of breath, and DM had an increased risk of hospitalization (table 4).
Factors associated with ICU admission and length of stay
The multivariable models also assessed the adjusted association between independent variables and outcomes of admission to ICU and length of stay in ICU. Here again, DM and increased respiratory rate were significantly associated with ICU admission (table 5). Spearman correlation analysis was used to assess the association between number of days in ICU and laboratory values (table 5). Numerous variables positively correlated with the extension of stay in ICU, which included advanced age, increased BMI, fever, tachypnea, leukocytosis, procalcitonin and lactic acid levels, elevated aspartate aminotransferase (AST) and alanine aminotransferase (ALT), extended partial thromboplastin time (PTT), hypokalemia, and D-dimer and troponin elevation (online supplemental table 3). On the other hand, blood pressure, SpO2, hemoglobin, lymphocyte count, and sodium and pH levels were negatively correlated with number of days in ICU (table 6).
Factors associated with mortality
In unadjusted analysis, a large number of variables were found to be associated with in-hospital mortality (online supplemental table 2). In multivariable analysis, individuals with increased levels of body temperature, decreased levels of SpO2, and increased age were found to be associated with an increased risk of mortality (table 7).
Data on COVID-19 in the Hispanic population have been scarce, and data on Hispanics living on the USA–Mexico border are still absent. We decided to evaluate variables that are known to influence the clinical course and severity of COVID-19 hospitalization, given the ethnic disparities in COVID-19 outcomes that translate into higher fatality rates for Hispanic and black populations compared with white non-Hispanics.7 8 Our study focused on a timeframe that represented the first surge of COVID-19 in the region, at a time when reports from the USA were mainly coming from New York and during which protocols for the use of certain interventions such as steroids, anticoagulation, or antivirals were not yet implemented.
Patients older than 50 years were more likely to present with fever, without any difference in other symptoms.9 It has been shown that the Hispanic/Latino population has a disease presentation with lower rates of fever, but higher rates of nasal symptoms, myalgia, headache, sore throat, and vomiting/diarrhea, compared with studies from China,10 11 but similar to European patients.12 Rhinorrhea has been, in fact, a factor associated with hospitalization.9
Initial reports from China showed that more than half of patients had an underlying medical condition, with HTN being the most common, followed by DM and coronary heart disease.11 We found that DM was a major factor associated with not only hospitalization but with admission to ICU. This is in line with recent meta-analyses on the role of comorbidity in increasing the risk of COVID-19 exacerbation.13 14 DM alone is associated with a twofold increase in mortality as well as severity of COVID-19.2
Several factors were also associated with severity, indicated by length of stay in the ICU. Age, fever, tachypnea, low SpO2, decreased hemoglobin, leukocytosis, and lymphopenia had been described in more severe patients since the beginning of the pandemic.3 Lymphopenia, which has been present in more than 83% of patients with COVID-19 on admission,3 15 is a cardinal laboratory finding with promising prognostic potential.16 17 Procalcitonin, lactic acid levels, elevated AST and ALT, and D-dimer elevation have also been described in the initial reports of COVID-19 severity in China.3 A hypercoagulable state has been observed in a subset of young adult patients with COVID-19, where elevated D-Dimer levels are associated with disease worsening.16
Our regression model yielded a list of factors associated with mortality, including advanced age, fever, and low SpO2. Epidemiological studies have shown increased mortality in men and elderly patients.4 18 The average age of patients in our studied population was 55 years, concordant with recent literature from China, where in-hospital deaths were associated with older age, precisely 55.5 years old.11 Lower SpO2 has also been shown to be a predictor of mortality in COVID-19.19 20 However, we did not observe mortality association with variables such as male gender,3 15 18 HTN, DM, use of hydroxychloroquine,19 21 ground-glass opacity as a radiological finding,15 18 22 D-dimer elevation,11 higher white cell count, elevated C reactive protein,21 and lymphopenia,17 which have appeared to be robust and consistent predictors of mortality in COVID-19.
Although the number of patients in this report is relatively small and there was not an established medical management, diagnostic and therapeutic protocol in El Paso, our findings are significant as they assess variables in a Hispanic population alone. The repeated appearance of risk factors such as DM in the analysis should prompt a red flag for allocation of expected public health measures such as vaccines. Research aiming to identify key evidence‐based prognostic factors in our patient population will help guide our healthcare providers so that best interventions can be implemented to improve the outcomes of patients with COVID-19. Further larger cohort studies, across the nation and across border states, should provide broader insights into how COVID-19 presents and behaves in the Hispanic population.
Contributors JC, MZ, and AM conceptualized the study. AS and GG collected the data. MB, CD, and AKD analyzed the data. JC, AS, GG, AKD, MZ, and AM wrote the manuscript.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Patient consent for publication Not required.
Ethics approval The Texas Tech University Health Sciences Center Institutional Review Board (IRB) acknowledged that this project meets the criteria for exemption from formal IRB review in accordance with 45 CFR 46.104(d)(4)(iii): The research involves only information collection and analysis involving the investigator’s use of identifiable health information when that use is regulated under 45 CFR parts 160 and 164, subparts A and E, for the purposes of 'healthcare operations' or 'research' as those terms are defined at 45 CFR 164.501. An HIPAA waiver has been approved under 45 CFR 164.512(i) (2)(ii), IRB#: E20137.
Provenance and peer review Not commissioned; externally peer reviewed.
Data availability statement No data are available.
Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.